---
title: "Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286665358.md"
description: "Analyst David Martin PhD of Bloom Burton has reiterated a Buy rating on Microbix Biosystems with a price target of C$0.40. He attributes the recent revenue shortfall to a temporary slowdown in Chinese antigen orders, not structural issues. Demand from non-Chinese customers is increasing, and Microbix has diversified its revenue base, reducing future volatility. This positioning, along with the potential for sales normalization, presents an attractive risk-reward profile."
datetime: "2026-05-17T07:35:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286665358.md)
  - [en](https://longbridge.com/en/news/286665358.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286665358.md)
---

# Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand

Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Microbix Biosystms, with a price target of C$0.40.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

David Martin PhD has given his Buy rating due to a combination of factors that point to Microbix’s underlying strength despite a weak quarter. He notes that the revenue shortfall was largely driven by a temporary pullback in Chinese antigen orders following an unusually light respiratory season, rather than by structural issues in the business, and that demand from non‑Chinese customers is already growing again, signaling a healthier baseline.

At the same time, he highlights that Microbix has diversified its revenue base beyond China and is demonstrating sequential growth in other markets, which should reduce future volatility. In his view, this positioning, combined with the prospect of sales normalization as inventories are worked down and the stock’s current valuation, offers an attractive risk‑reward profile that justifies a Buy recommendation.

### Related Stocks

- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [MBX.US](https://longbridge.com/en/quote/MBX.US.md)

## Related News & Research

- [United Labs says China regulator clears TUL108 injection for clinical trial](https://longbridge.com/en/news/286902656.md)
- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [Pizza Pizza Royalty slashes monthly dividend by 12.9% to CAD 0.0675 a share](https://longbridge.com/en/news/286714154.md)
- [High Liner Foods declares CAD 0.175 dividend](https://longbridge.com/en/news/286382844.md)
- [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)